327 related articles for article (PubMed ID: 11772236)
1. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
Mitsiades N; Poulaki V; Mitsiades CS; Anderson KC
Expert Opin Investig Drugs; 2001 Jun; 10(6):1075-84. PubMed ID: 11772236
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.
Mitsiades N; Yu WH; Poulaki V; Tsokos M; Stamenkovic I
Cancer Res; 2001 Jan; 61(2):577-81. PubMed ID: 11212252
[TBL] [Abstract][Full Text] [Related]
3. Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors.
Mitsiades N; Poulaki V; Leone A; Tsokos M
J Natl Cancer Inst; 1999 Oct; 91(19):1678-84. PubMed ID: 10511596
[TBL] [Abstract][Full Text] [Related]
4. Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology.
Webb SD; Sherratt JA; Fish RG
Math Biosci; 2002; 179(2):113-29. PubMed ID: 12208611
[TBL] [Abstract][Full Text] [Related]
5. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
Zucker S; Cao J; Chen WT
Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
[TBL] [Abstract][Full Text] [Related]
6. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells.
Nyormoi O; Mills L; Bar-Eli M
Cell Death Differ; 2003 May; 10(5):558-69. PubMed ID: 12728254
[TBL] [Abstract][Full Text] [Related]
7. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis.
Powell WC; Fingleton B; Wilson CL; Boothby M; Matrisian LM
Curr Biol; 1999 Dec 16-30; 9(24):1441-7. PubMed ID: 10607586
[TBL] [Abstract][Full Text] [Related]
8. The role of Fas and FasL as mediators of anticancer chemotherapy.
Poulaki V; Mitsiades CS; Mitsiades N
Drug Resist Updat; 2001 Aug; 4(4):233-42. PubMed ID: 11991678
[TBL] [Abstract][Full Text] [Related]
9. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
[TBL] [Abstract][Full Text] [Related]
10. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis.
Ii M; Yamamoto H; Adachi Y; Maruyama Y; Shinomura Y
Exp Biol Med (Maywood); 2006 Jan; 231(1):20-7. PubMed ID: 16380641
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.
Pavlaki M; Zucker S
Cancer Metastasis Rev; 2003; 22(2-3):177-203. PubMed ID: 12784996
[TBL] [Abstract][Full Text] [Related]
13. Modulation of death receptor pathways in oncology.
de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
Yang JS; Lin CW; Su SC; Yang SF
Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
[TBL] [Abstract][Full Text] [Related]
15. Fas ligand/Fas-mediated apoptosis in human coronary artery smooth muscle cells: therapeutic implications of fratricidal mode of action.
Belanger AJ; Scaria A; Lu H; Sullivan JA; Cheng SH; Gregory RJ; Jiang C
Cardiovasc Res; 2001 Sep; 51(4):749-61. PubMed ID: 11530108
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis.
Frost PJ; Belldegrun A; Bonavida B
Prostate; 1999 Sep; 41(1):20-30. PubMed ID: 10440872
[TBL] [Abstract][Full Text] [Related]
17. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes.
Winer A; Adams S; Mignatti P
Mol Cancer Ther; 2018 Jun; 17(6):1147-1155. PubMed ID: 29735645
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase inhibitors.
Ramnath N; Creaven PJ
Curr Oncol Rep; 2004 Mar; 6(2):96-102. PubMed ID: 14751086
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases as therapeutic targets in cancer.
Vihinen P; Ala-aho R; Kähäri VM
Curr Cancer Drug Targets; 2005 May; 5(3):203-20. PubMed ID: 15892620
[TBL] [Abstract][Full Text] [Related]
20. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.
Odoux C; Albers A; Amoscato AA; Lotze MT; Wong MK
Int J Cancer; 2002 Feb; 97(4):458-65. PubMed ID: 11802207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
